These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 34309158)
1. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients. Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158 [TBL] [Abstract][Full Text] [Related]
2. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity. Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964 [TBL] [Abstract][Full Text] [Related]
3. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients. Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768 [TBL] [Abstract][Full Text] [Related]
4. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286 [TBL] [Abstract][Full Text] [Related]
5. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999 [TBL] [Abstract][Full Text] [Related]
6. Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction. Winstead RJ; Kumar D; Brown A; Yakubu I; Song C; Thacker L; Gupta G Transpl Infect Dis; 2021 Aug; 23(4):e13570. PubMed ID: 33469975 [TBL] [Abstract][Full Text] [Related]
7. Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients. Golob S; Batra J; DeFilippis EM; Uriel M; Carey M; Gaine M; Mabasa A; Fried J; Raikelkar J; Restaino S; Hi Lee S; Latif F; Yuzefpolskaya M; Colombo PC; Choe J; Majure D; Jennings D; Pereira MR; Clerkin K; Sayer G; Uriel N Clin Transplant; 2022 Dec; 36(12):e14808. PubMed ID: 36086937 [TBL] [Abstract][Full Text] [Related]
8. Letermovir treatment for CMV infection in kidney and pancreas transplantation: A valuable option for complicated cases. Ortiz F; Lempinen M; Aaltonen S; Koivuviita N; Helanterä I Clin Transplant; 2022 Feb; 36(2):e14537. PubMed ID: 34797574 [TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report. Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819 [TBL] [Abstract][Full Text] [Related]
10. Five-year single-center analysis of cytomegalovirus viremia in kidney transplant recipients and possible implication for novel prophylactic therapy approaches. Trappe M; Affeldt P; Grundmann F; Kann M; Koehler FC; Müller RU; Stippel D; Kaiser R; Knops E; Heger E; Steger G; Klein F; Kurschat C; Di Cristanziano V Transpl Infect Dis; 2024 Feb; 26(1):e14233. PubMed ID: 38180168 [TBL] [Abstract][Full Text] [Related]
11. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients. Phoompoung P; Ferreira VH; Tikkanen J; Husain S; Viswabandya A; Kumar D; Humar A Transplantation; 2020 Feb; 104(2):404-409. PubMed ID: 32000236 [TBL] [Abstract][Full Text] [Related]
12. A Case Report of Successful Use of Twice-Daily Letermovir in the Treatment of Resistant Cytomegalovirus in a Small Bowel Transplant Recipient. Joharji H; Alaidaros F; Koujan H; Hamad A; Almaghrabi RS; Zidan A; Broering D; Al-Jedai A Transplant Proc; 2022; 54(6):1679-1681. PubMed ID: 35842318 [TBL] [Abstract][Full Text] [Related]
13. [Novelties for the management of cytomegalovirus after kidney transplantation]. Kamar N; Marion O; Del Bello A Nephrol Ther; 2024 Aug; 20(4):269-276. PubMed ID: 39129511 [TBL] [Abstract][Full Text] [Related]
14. Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation. Jorgenson MR; Wong C; Descourouez JL; Saddler CM; Smith JA; Mandelbrot DA Transpl Infect Dis; 2021 Aug; 23(4):e13617. PubMed ID: 33866643 [TBL] [Abstract][Full Text] [Related]
15. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755 [TBL] [Abstract][Full Text] [Related]
16. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients. Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437 [TBL] [Abstract][Full Text] [Related]
17. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420 [TBL] [Abstract][Full Text] [Related]
18. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients. Razonable RR Clin Microbiol Infect; 2023 Sep; 29(9):1144-1149. PubMed ID: 36963566 [TBL] [Abstract][Full Text] [Related]
19. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature. Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830 [TBL] [Abstract][Full Text] [Related]
20. Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients. Verghese PS; Evans MD; Hanson A; Hathi J; Chinnakotla S; Matas A; Balfour HH J Clin Virol; 2024 Jun; 172():105678. PubMed ID: 38688164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]